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Background: Advanced liver disease predisposes to bacterial translocation and endotoxaemia which can contribute to
elevated circulating levels of IL-10 and down-regulation of MHC class II on antigen-presenting cells. We sought to
evaluate antigen-specific T-cell responses toward common viral antigens in order to investigate defects in cellular
immunity in cirrhosis.
Methods: Peripheral blood was obtained from 22 cirrhotic patients with systemic inflammation, 13 cirrhotic patients
without systemic inflammation and 14 healthy controls. C-reactive protein was used as an indicator for systemic
inflammation using a cut-off of 10 mg/l. Intracellular Th1 cytokines were quantified after T cell-stimulation with the viral
peptides EBNA1 and BZLF1 or the bacterial superantigen SEB by flow cytometry. Serum levels of lipopolysaccharide-
binding protein (LBP) and IL-10 were quantified by ELISA.
Results: Compared to healthy controls, patients with cirrhosis had higher circulating levels of LBP and IL-10, an expansion
of peripheral blood CD14+ monocytes with low HLA-DR expression and an increased fraction of CD25-positive CD4+ and
CD8+ T cells. These findings were most pronounced in cirrhotic patients with systemic inflammation but fell short of
reaching statistical significance when comparing against cirrhotic patients without systemic inflammation. In the former
group TNF-α production in CD4+ and CD8+ T cells was reduced after stimulation with SEB, whereas there was no
significant difference between the total cohort of cirrhotic patients and controls. After stimulation with the overlapping
peptide pools for viral antigens EBNA1 and BZLF1, the number of responding T cells and the amount of TNF-α or IFN-γ
production did not differ between the three pre-defined groups. However, cirrhotic patients with null-responses to EBV
peptides had significantly higher serum IL-10 levels than responders to EBV peptides. Furthermore, TNF-α production in
responding T cells was attenuated in patients with a high frequency of CD14+ HLA-DR- monocytes.
Conclusion: Our data suggest that bacterial translocation, endotoxaemia, inflammation and T cell activation in cirrhosis
are accompanied by an increase in circulating anti-inflammatory cytokines, reduced monocytic MHC class II expression
and attenuated cytokine production in T cells. These changes are likely to contribute to altered adaptive immune
responses during infection or after vaccination.
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Alterations of the immune system are very common in
patients with end-stage liver disease and associated with
an increased risk of infection and death [1-3]. Func-
tional abnormalities of neutrophils and macrophages
[4-8], natural killer cells [9], and the complement
system [10] contribute to impaired innate immune
responses and have been well described. There is also
evidence to suggest that the adaptive immune response
is defective in chronic liver disease, and cell-mediated
immune responses after vaccination for hepatitis A,
hepatitis B, or influenza are frequently attenuated in
patients with decompensated liver cirrhosis. [11,12]. Al-
though T cell responses towards hepatitis B virus and
hepatitis C virus have been extensively studied [13,14],
little is known about the T cell response to persistent
other viruses such as Epstein-Barr Virus (EBV) as a
marker of cellular immune function in cirrhosis.
In general, unresponsiveness of the adaptive immune
system to antigens can be attributed to either a defect in
antigen presentation by dendritic cells and macro-
phages, or to a suppressed or deficient T cell response.
Cirrhosis predisposes to recurrent episodes of subclin-
ical translocation of intestinal bacteria and bacterial
products resulting in increased levels of endotoxin
(lipopolysaccharide [LPS]) and tumour necrosis factor-
alpha (TNF-α) [15]. Augmented by TNF-α, LPS is able
to induce the secretion of interleukin-10 (IL-10) from
Kupffer cells into the circulation [16,17], which can act
as an inhibitor of cellular proliferation and T cell-
mediated cytokine responses. This occurs in part
through a down regulation of major histocompatibility
complex (MHC) class II on monocytes/macrophages
and inhibition of T-cell co-stimulatory pathways
[18,19]. Indeed, reduced expression of MHC class II on
monocytes has been observed in critically ill patients
with cirrhosis [20,21] and in those with acute-on
-chronic liver failure [22] and correlates with increased
mortality. However, reduced monocyte HLA-DR ex-
pression also occurs in non-cirrhotic patients after
trauma, during the systemic inflammatory response syn-
drome (SIRS) and sepsis [23,24]. SIRS is a frequent
finding in patients with cirrhosis and is itself associated
with poor outcome. [25] However, it is not known
whether these phenotypic alterations occur in less se-
verely ill cirrhotic patients (without SIRS) in association
with endotoxaemia, and if present whether they contrib-
ute to functional T cell impairment.
To investigate the cellular immune status in cirrhosis,
we studied T cell responses in vitro and their association
with markers of bacterial translocation, serum IL-10,
monocyte HLA-DR expression and T cell subsets in cir-
rhotic patients without SIRS. Healthy volunteers served
as our controls.Methods
Setting and participants
35 patients with liver cirrhosis presenting to our depart-
ment between October 2009 and March 2010 and 14
self-declared healthy individuals were included. All
subjects provided informed consent and local ethics
committee approval was obtained. Liver cirrhosis was
confirmed histologically, or through a combination of
clinical, biochemical, and imaging data at the discretion
of the investigator. Individuals were excluded if they met
two or more criteria for systemic inflammatory response
syndrome (SIRS) [26], if they were receiving immuno-
suppressive therapy, underwent surgical intervention
within the last month, consumed alcohol within the last
three days, experienced an episode of gastrointestinal
bleeding, or underwent any endoscopic intervention
within the last three days before inclusion. C-reactive
protein (CRP) concentrations were measured as an indi-
cator for systemic inflammation by routine laboratory
analysis. Using the cut-off of 10 mg/l for cirrhotic
patients defined by Papp et al. [27].
Blood sampling and flow cytometry
9 ml heparinised whole blood and 9 ml EDTA whole
blood samples (Sarstedt AG & Co, Nümbrecht, Germany)
were collected, stored at 4°C, measured within 2 hours for
cell surface receptors and stimulated with peptide pools
within 3 hours. Briefly, 100 μl EDTA whole blood was
stained for 20 min with fluorochrome-labelled monoclo-
nal antibodies against HLA-DR (FITC, F7266; Dako,
Hamburg, Germany), CD14 (PE, F0844; Dako), CD4
(FITC; F0766; Dako), CD8 (PE; R0806; Dako) and or
CD25 (APC; 17–0259; eBioscience, Frankfurt, Germany)
and washed in FACS buffer solution (PBS with 0.25% BSA
and 0.02% sodium azide). When indicated, red blood cells
were lysed using FACS lysing solution (BD Biosciences,
Heidelberg, Germany) prior to staining. More than 50,000
PBMC were collected on a BD LSR II flow cytometer (BD
Biosciences). Monocytes and lymphocyte populations
were identified by the use of forward and right angle light
scatter and by CD14, CD4 or CD8, respectively. The per-
centage of HLA-DR-expressing monocytes was calculated
as the percentage of HLA-DR+ cells of total CD14+ cells;
the percentage of CD25-expressing T cells was calculated
as the percentage of CD25+ T cells of the CD4+ or CD8+
T cell population.
For intracellular cytokine staining, 500 μl heparinised
whole blood was stimulated with peptide mixtures for 6
h at 37°C and 5% CO2 in the presence of 1 μg/ml co-
stimulatory monoclonal antibodies to CD28 (L293) and
CD49d (L25; BD Biosciences), and 10 μg/ml Brefeldin A
(Sigma-Aldrich, Hamburg, Germany) as golgi-stop. The
peptide pools (15-mers with 11 amino-acid overlaps) for
Epstein-Barr nuclear antigen 1 (EBNA1) (130-093-613;
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BamHI Z fragment leftward open reading frame number
1 (BZLF1) (130-093-611; Miltenyi) were added at a final
concentration of 0.6 nM per reaction. The superantigen
Staphylococcal enterotoxin B (SEB) was added at a final
concentration of 1.5 μg/ml. After 6 hours incubation, 4
μl 0.5 M EDTA and 4.5 ml FACS lysing solution were
added and cells resuspended in 1ml of permeabilising
solution (0.25% BSA, 0.02% sodium azide, 0.5% saponin
in PBS) for 10 min. After an additional centrifugation
step, cells were stained with fluorochrome-labelled anti-
bodies against CD4 (FITC) and CD8 (PE), IFN-γ (Pacific
Blue; Invitrogen, Darmstadt, Germany), TNF-α (APC;
Invitrogen) for 20 min at room temperature. Cells were
washed and resuspended in 300 μl of FACS buffer solu-
tion (0.25% BSA and 0.02% sodium azide in PBS).
Negative samples without antigen stimulation were
performed within each run. Positive cytokine responses
were defined as a cell frequency of at least 2-fold above
background (negative control without antigen) with a
minimum of 50 cytokine-positive cells as previously
described [28]. Cytometer setup and daily quality control
of the instrument’s stability was performed by the
cytometer setup and tracking module included into the
FACS DiVa software package. Frequencies and median
fluorescence intensities of labelled cells were calculated
using FlowJo software (Tree Star, Ashland, OR, USA).
Measurement of circulating interleukin-10 (IL-10) and
lipopolysaccharide-binding protein (LBP)
Determination of serum concentrations of IL-10 and LBP
was performed in 36 and 39 subjects, respectively. Serum
LBP concentrations was measured in duplicate with the
HK315 human LBP sandwich ELISA (Hycult Biotech,
Uden, Netherlands; lower limit of detection 1 ng/ml) after
dilution according to the manufacturer’s instructions. The
standard curve was created from a 6-fold series of
dilutions of a 50 μg/ml standard in duplicate. Serum IL-10
was determined using the ELISA MAX human IL-10
assay (Biolegend, San Diego, CA, USA; lower limit of de-
tection 2 pg/ml) in duplicate according to manufacturer’s
instructions. The standard curve was created from a
6-fold series of dilutions of a 250 pg/ml stock concentra-
tion. Measurements were performed using a photometric
plate reader (VICTOR, Wallac, USA) at 460 nm.
Statistical analysis
Baseline patient characteristics were reported as median
and range for continuous variables, or as a frequency for
discrete variables. Statistical analysis for nonparametric
data was performed by using Mann–Whitney U test,
Kruskal-Wallis test with post hoc Dunn’s test or
Jonckheere-Terpstra test as appropriate. Bivariate correl-
ation was either performed by the calculation of non-parametric Spearman’s correlation coefficient Rs or by
Pearson’s linear correlation coefficient R. Statistical
calculations were performed using SPSS v.16 (SPSS Inc.,




22 (63%) patients with cirrhosis had elevated CRP levels
>10 mg/l. Causes were bacterial infections in 5 patients
(2× SBP, 3× culture-positive urinary tract infections), in-
flammatory skin lesions in 3 patients, sterile pyuria in 4
patients and oedematous pancreatitis in 1 patient. An in-
flammatory focus could not be detected in 9 patients.
None of the 13 cirrhotic patients with low CRP levels
presented with clinically manifested bacterial infection.
Cirrhotic patients that presented with signs of systemic
inflammation more often had advanced liver disease
indicated by ascites (Table 1). As expected, LBP serum
levels were elevated in cirrhosis, but they did not differ
with regards to the inflammation status as indicated by
elevated CRP levels (Figure 1A). Concomitantly, IL-10
serum concentrations were elevated in patients with cir-
rhosis (Figure 1B) showing a trend of a positive linear
correlation between serum IL-10 and LBP (Figure 1C).
MHC class II expression on CD14+ monocytes is reduced
in cirrhosis
The fraction of circulating monocytes within leukocytes
was 6% (range: 3–12%) in controls, 8% (range: 3–20%) in
cirrhotic patients without inflammation and 9% (range:
5–23%) in patients with cirrhosis and inflammation
(P=0.008; Kruskal-Wallis test). In patients with cirrhosis,
HLA-DR expression on CD14+ monocytes was reduced in
cirrhosis (median 90.6%; range: 29.3%–100%) compared to
controls (median 99.9%; range 93.7%–100%) (P<0.0001),
whereas there was no significant difference with respect to
the inflammation status in cirrhosis (Figures 2A and 2B).
Accordingly, the surface HLA-DR expression on CD14
+HLA-DR+ monocytes was markedly reduced in patients
with cirrhosis as shown by a decreased mean fluorescence
intensity (MFI; Figure 1C). However, there was no signifi-
cant correlation between the fraction of HLA-DR-
monocytes or HLA-DR MFI on CD14+ monocytes with
serum IL-10, serum LBP, Child-Pugh score or MELD
score (P>0.4).
The fraction of CD25+ T cells is increased in cirrhosis
Inversely to the monocyte fraction, circulating lymphocytes
were lower in patients with cirrhosis and inflammation
(median 26%; range 14%–79%) than in patients with cirrho-
sis without inflammation (38%; range 21%–95%) and in
control subjects (51%; range 26%–66%) (P=0.014; Kruskal-
Wallis test). Although the CD4/CD8 ratio did not differ












Years of age – median (range) 39 (22–52) 55 (37–81) 65 (44–82) <0.001
Male sex – no. (%) 8 (57%) 7 (54%) 14 (64%) n.s.
Positive Epstein-Barr virus serology – no. (%) 12/14 (85%) 11/11 (100%) 25/25 (100%) n.s.
LBP serum concentration (μg/ml) – median (range) 14 (7–22) 30 (12–44) 33 (10–50) 0.002
IL-10 serum concentration (pg/ml) – median (range) 4 (3–7) 10 (6–37) 14 (7–51) <0.001
Alcoholic aetiology of cirrhosis – no. (%) 8 (62%) 15 (68%) n.s.
Child-Pugh stage A/B/C – no. 6/4/3 2/3/17* 0.005
Child-Pugh score – median (range) 7 (5–13) 10 (6–13)* 0.005
Ascites – no. (%) 5 (38%) 19 (86%)* 0.007
MELD score – median (range) 12 (6–24) 16 (7–33) n.s
Laboratory values - median (range)
Total serum bilirubin - μmol/l 31 (5–504) 49 (7–324) n.s
International normalized ratio 1.2 (0.9–2.0) 1.4 (1.1–2.2)* 0.029
Creatinine - μmol/l 76 (50–129) 91 (52–235) n.s
Aspartate aminotransferase - μmol/l×s 0.78 (0.46–4.16) 1.23 (0.30–3.42) n.s
Alanine aminotransferase - μmol/l×s 0.77 (0.36–2.68) 0.61 (0.24–1.10) n.s
White blood cell count – Gpt/l 5.8 (2.4–7.2) 6.6 (3.6–16.8)* 0.034
C-reactive protein – mg/l 4.9 (2.0–10.0) 25.5 (12.6–91.9)* <0.001
Serum Albumin – g/l 31 (19–40) 27 (17–35) n.s.
P values in Kruskal-Wallis test or Mann–Whitney U test for continuous data or Fisher’s exact test for discrete data are indicated. * indicates a statistical significant
difference between cirrhotic patients with and without elevated C-reactive protein levels.
MELD: Model for end-stage liver disease score, n.s.: not significant (P≥0.05).
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had a significantly increased fraction of CD25+ CD4+ Tcells
and CD25+ CD8+ T cells, a finding most pronounced in
patients with evidence of inflammation (Figures 3A, 3B
and 3C). The fractions of CD25-positive CD4+ and CD25+BA


































Figure 1 Serum levels of lipopolysaccharide-binding protein (LBP) an
serum levels of (A) LBP and (B) IL-10 in healthy controls (cntrl) and cirrhotic
are indicated for cirrhotic patients when stratified for inflammation (+/−infl
Whitney U test are indicated; n.s. = not significant. (C) Serum concentration
fashion. Linear regression curve, Pearson product–moment correlation coefCD8+ T cells correlated significantly in a linear fashion
(R=0.433; P=0.01) (Figure 3D). Moreover, the fraction of
CD25+ CD4+ cells positively correlated with serum IL-10
(Rs=0.508; P=0.011) and tended to correlate with serum





















d interleukin-10 (IL-10) are increased in cirrhosis. Box-plots of
patients (cirrh) are indicated (left). Scattered dot plots and medians
) as evidenced by elevated CRP levels (right). P values in Mann–
s of IL-10 and LBP in cirrhotic patients tend to correlate in a linear
ficient R and P value are indicated.
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cirrhotic patients with on-going inflammation
After stimulation of whole blood with the superantigen
SEB, which cross-links the T cell receptor to MHC class
II, all control subjects and all cirrhotic subjects without in-
flammation had a positive cytokine response for TNF-α
and IFN-γ in both CD4+ and CD8+ T cell subsets (2-fold
increase of responding cells), whereas 5 of 22 (23%)
cirrhotic patients with inflammation had not (Figures
4A and 4B). The fraction of IFN-γ-producing or TNF-
α-producing CD4+ and CD8+ cells after SEB differed
significantly between cirrhotic patients with inflammation
than in cirrhotic patients without inflammation (Figure 4C).
Furthermore, TNF-α production in responding CD4+ and
CD8+ T cells was lower in cirrhotics with inflammation
than in cirrhotic patients without evidence of inflammation





































Figure 2 Monocyte HLA-DR expression on CD14+ monocytes is reduc
monocyte HLA-DR expression using flow cytometry. Monocytes were ident
CD14-positive cells (middle). The overlay histogram (right) demonstrates HL
individuals from the control group (cntrl, grey area), from the cirrhosis grou
group with inflammation (cirrh +infl, grey line). Panels B and C display distr
monocytes (B) and of mean fluorescence intensity of HLA-DR+ CD14+ mon
with cirrhosis (left) and from patients with cirrhosis when stratified for elev
n.s. = not significant.and CD8+ Tcells after SEB stimulation negatively correlated
with CRP levels (Rs=−0.439 [P=0.008] and Rs=−0.443
[P=0.008], respectively) but not with IL-10 (P=0.709;
P=0.408), MELD score (P=0.499; P=0.264) or Child-Pugh
score (P=0.545; P=0.243) in non-parametric correlation, in-
dicating cellular exhaustion in patients with severe acute
phase reaction.
Attenuated T cell responses to EBNA1 and BZLF1 are
associated with higher interleukin-10 levels and low
monocyte HLA-DR expression in cirrhotic patients
All cirrhotic patients and 12 of 14 control subjects were
seropositive for EBV antibodies against EBNA as
determined by immunoblot, indicating previous EBV in-
fection. After stimulation of whole blood with overlap-
ping peptide pools for the viral antigens EBNA1 and




















ed in cirrhosis. Panel A displays the gating strategy to determine
ified by forward and sideward scatter (left) and subsequent gating on
A-DR expression on CD14+ monocytes of three representative
p without inflammation (cirrh –infl, black line) and from the cirrhosis
ibution and median of fraction of HLA-DR-expressing CD14+
ocytes (C) from healthy controls and patients
ated CRP (right). P values in Mann–Whitney U test are indicated;





















































































































































Figure 3 Increased fraction of CD25+ T cells in cirrhosis. (A) Gating strategy (left) and representative plots of CD25 expression on CD4 T cells
in a healthy control (middle) and a patients with cirrhosis (right). Panels B and C display distribution and median of CD25-positive CD4+ T cells (B)
and CD8+ T cells (C) in healthy controls and patients with cirrhosis (left) and in cirrhotics stratified for inflammation (right). P values in Mann–
Whitney U test are indicated; n.s. = not significant. (D) Correlation of CD4+ CD25+ T cells and CD8+ CD25+ T cells in cirrhotic individuals. Linear
regression curve, Pearson product–moment correlation coefficient R and P value are indicated. Panels E and F show the correlation of percentage
of CD25-positive CD4+ T cells with IL-10 serum concentration (E) and LBP serum concentration (F) in patients with cirrhosis (black diamonds) and
controls (grey circles), respectively. Spearman’s correlation coefficient Rs and P value are indicated for the cirrhotic patients.
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number of positive cytokine (TNF-α, IFN-γ) responses in
CD4+ and CD8+ cells, represented as the sum of a positive
response of each combination (score 0–4). The median
number of positive responses after EBNA1 and BZLF1 ex-
position did not differ significantly between the threegroups, which held also true in analyses performed sepa-
rately for CD4 and CD8 T cell responses. Furthermore,
intracellular cytokine production in responding T cells
was not altered with respect to the three observation
groups (data not shown). However, the fraction of patients


































































































































































Figure 4 (See legend on next page.)
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Figure 4 T cell responses towards the viral antigens EBNA1 and BZLF1 and the superantigen SEB in cirrhosis. (A) Representative plots of
intracellular cytokine staining for TNF-α and IFN-γ in T cells after stimulation with SEB. (B) Distribution and median of T cell responses after stimulation with
SEB, EBNA1 and BZLF1 in controls (circles), cirrhotic patients without inflammation (diamonds) and cirrhotic patients with inflammation (triangles). A
positive response was defined as a cytokine-positive cell frequency of at least 2-fold above background (no antigen control) and the responses for TNF-α
in CD4+ and CD8+ cells and for IFN-γ in CD4+ and CD8+ cells were added to a total score of 0 to 4. (C) Median and distribution of reacting CD4 T cells
(left) and CD8 T cells (right) after SEB stimulation in cirrhotic patients with and without inflammation (+/−infl). ** indicates P values <0.01 in Mann–Whitney
U test. (D) Mean florescence intensity (MFI) and standard error of mean are indicated for the intensity of TNF-α or IFN-γ response in CD4+ and CD8+ T cells
after stimulation with SEB. P-values indicate results in Kruskal-Wallis test for each cytokine and T cell subset and asterisks indicate significance level in post-
hoc Dunn’s multiple comparison test (* P<0.05; ** p<0.01). (E) Serum IL-10 levels from cirrhotic patients with a null response according to the
aforementioned criteria (0) and from cirrhotic patients with at least one cytokine response (+) after stimulation with EBNA1 and BZLF1 are indicated
(available from 25 cirrhotic patients). Patients were either stratified for the presence of a null response to EBNA1 or BZLF1 (left; P value in Mann–Whitney U
test is indicated) and stratified for the combination of null-responses towards EBNA1 and BZLF1 (right; Jonckheere-Terpstra test demonstrates an increase
in IL-10 in patients across the groups).
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mation (9/22 [41%] and 7/22 [32%], respectively) than in
cirrhosis without inflammation (3/13 [23%] and 3/13
[23%]) or in controls (3/12 [25%] and 0/12 [0%]). Cirrhotic
null-responders to any of the viral antigens EBNA1 or
BZLF1 had higher IL-10 levels than cirrhotic patients with
at least one positive response (P=0.005) (Figure 4E). IL-10
serum levels in cirrhosis significantly increased from
responders through null-responders towards one of the
viral antigens to null-responders to both viral antigens
(P for trend = 0.003; Jonckheere-Terpstra test) (Figure 4E).
Furthermore, patients with a low fraction of HLA-DR+
CD14+ monocytes <70% had a lower number of TNF-
α-producing CD4+ T cells after stimulation with EBNA1
(median 0.02% vs. 0.05%; P=0.019). No correlation was
found between low HLA-DR expression on CD14+
monocytes and TNF-α response in CD8+ T cells towards
EBNA1 or BZLF1 peptides in cirrhotic patients (P=0.817
and P=0.976, respectively).
Discussion
In this study we determined T cell responses towards EBV
as a model to investigate the cellular immune function
in patients with cirrhosis. Cirrhotic patients displayed
elevated markers of bacterial translocation and increased T
cell activation as well as reduced monocyte MHC class II
expression and increased IL-10 serum levels. This pheno-
type was more pronounced in cirrhotic patients with sys-
temic inflammation although did not reach statistical
significance. We were not able to demonstrate significantly
decreased antigen-specific T cell responses in the pre-
defined patient cohorts. However, patients with diminished
T cell responses towards the aforementioned viral proteins
had significantly higher serum concentrations of IL-10
than patients with unaltered T cell responses.
It has been reported that HLA-DR expression on
monocytes is increased on circulating classical and non-
classical monocytes in patients with cirrhosis in the ab-
sence of bacterial infections and SIRS [29] but is reduced
in critically ill cirrhotic patients [21]. In our cohort,patients with cirrhosis presented with reduced monocytic
HLA-DR expression even in the absence of SIRS and
sepsis. IL-10 impairs MHC class II recycling leading to
decreased surface expression of HLA-DR [30], and a nega-
tive correlation of IL-10 and monocyte HLA-DR expres-
sion has been observed in patients with sepsis [31]. Indeed,
we also observed high circulating IL-10 levels in cirrhotic
patients which positively correlated with the degree of bac-
terial translocation as indicated by serum LBP concentra-
tion. Cells of monocyte-macrophage lineage secrete IL-10
in response to endotoxin [16] and their secretion capacity
is not impaired but even pronounced in alcoholic cirrhosis
[32]. The major source of circulating IL-10 in endotoxemia
and abdominal infections are presumably Kupffer cells
which are exposed to gut-derived LPS via the portal vein
[16,17]. Besides elevated IL-10 concentrations, low serum
levels of IFN-γ might have contributed to the impaired
monocyte HLA-DR expression as observed in patients
with alcoholic cirrhosis [33,34]. However, we did not ob-
serve a significant correlation of HLA-DR expression on
CD14+ monocytes with liver function or stage of cirrhosis
or circulating IL-10 levels.
In this study, we describe several characteristics in T cell
phenotype and function in patients with cirrhosis. Despite
a decrease in the lymphocyte population, the population
of CD25-positive CD4+ and CD8+ T cells was expanded,
and attenuated T cell responses to the SEB were more
often observed in patients with cirrhosis and on-going in-
flammation. It remains unclear whether a reduction of
MHC class II directly contributes to impaired antigen
presentation to CD4 cells because even a low number of
MHC class II molecules on antigen-presenting cells is
sufficient to generate an effective T cell response [35] and
a compensatory up-regulation of co-stimulatory molecules
CD80 and CD86 has been observed on monocytes from
cirrhotic patients [36]. Responses to SEB are dependent
on HLA expression, since the superantigen cross-links
MHC class II on monocytes with the T-cell receptor
leading to a strong induction of TNF-α in T cells via pro-
tein kinase C [37]. Despite increased phenotypical markers
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fraction of T cells with cytokine responses to SEB as well
as reduced TNF-α production in CD4+ and CD8+ T cells
after stimulation with SEB. The cytokine response toward
the viral antigens EBNA1 and BZLF1 was not as distinct
as the response to SEB with high inter-individual variabil-
ity and no conclusive evidence for overall impaired T cell
responses in cirrhosis. Besides down-regulation of MHC
class II on monocytes, circulating IL-10 may also directly
attenuate T cell responses by inhibition of the co-
stimulatory CD28 signalling pathway [19]. Notably, we
observed higher serum IL-10 concentrations in patients
with a null response towards EBNA1 and/or BZLF despite
the presence of anti-EBNA antibodies indicative of past
EBV infection and immunoserological memory.
In addition to the observed pattern of attenuated T cell
responses in patients with low monocytic HLA-DR ex-
pression or high circulating IL-10 levels, one can speculate
that the presence of immune-regulatory subsets may also
have contributed to attenuated T cell responses. Márquez
et al. [36] reported that in patients with decompensated
cirrhosis, an increase in CD25-positive effector CD4+ T
cells was also accompanied by an increase of CD4+
CD25high Foxp3+ regulatory T cells that may suppress T
cell responses. This assumption, however, could not be
corroborated in our study since we did not prove these
cells to be CD127low and Foxp3-positive. Moreover, a sub-
set of CD14+ cells with low HLA-DR expression have re-
cently been reclassified as myeloid-derived suppressor
cells, and expand during infection or inflammation where
they are capable of suppressing T cell responses and in-
duce CD4+ CD25+ Foxp3+ regulatory T cells [38,39].
A further limitation of our study is that we did not
correct for HLA restrictions as being responsible for non-
response to stimulation with viral peptides. However,
among the EBV antigens several epitopes of the latent pro-
tein EBNA1 and the immediate early lytic peptide BZLF1
are rather promiscuous in the MHC class I and II context
[40]. Furthermore, our observations are in line with clin-
ical observations: although cirrhosis may worsen the
course of viral infections and vice versa [41,42], there is
no strong evidence that cirrhosis itself predisposes to viral
infections or other T cell defect-associated infections such
as tuberculosis [43].
Conclusions
Although this ex vivo study failed to provide evidence for a
disturbed T cell response in cirrhotic patients in general,
we did observe a pattern of attenuated responses towards
viral antigens in patients that display low monocytic HLA-
DR expression and/or increased serum IL-10 levels. Our
data suggest that bacterial translocation, endotoxaemia,
inflammation and T cell activation in cirrhosis are also ac-
companied by an increase in circulating anti-inflammatorycytokines, reduced monocytic MHC class II expression
and attenuated cytokine production in T cells, which are
likely to contribute to altered adaptive immune responses
during infections or after vaccination in vivo.
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